Silvan Tuerkcan
Stock Analyst at Citizens
(4.31)
# 327
Out of 5,174 analysts
176
Total ratings
47.13%
Success rate
18.61%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $46.43 | +85.23% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $50.00 | +14.00% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $4.28 | +133.64% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $6.90 | +204.35% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $12.81 | +63.93% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $4.13 | +93.70% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $10.70 | +105.61% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.15 | +421.74% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $11.28 | +201.42% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $30.53 | +47.40% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $41.57 | +20.28% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $6.68 | +124.55% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.52 | +70.45% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.80 | +87.50% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $12.15 | +887.65% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.58 | +975.95% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $3.18 | +25.79% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $9.44 | +122.46% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.73 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.23 | +85.76% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $72.37 | +286.90% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.36 | +58.45% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $46.43
Upside: +85.23%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $50.00
Upside: +14.00%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.28
Upside: +133.64%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $6.90
Upside: +204.35%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $12.81
Upside: +63.93%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.13
Upside: +93.70%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $10.70
Upside: +105.61%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.15
Upside: +421.74%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $11.28
Upside: +201.42%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $30.53
Upside: +47.40%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $41.57
Upside: +20.28%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $6.68
Upside: +124.55%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.52
Upside: +70.45%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.80
Upside: +87.50%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $12.15
Upside: +887.65%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.58
Upside: +975.95%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $3.18
Upside: +25.79%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $9.44
Upside: +122.46%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.73
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.23
Upside: +85.76%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $72.37
Upside: +286.90%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.36
Upside: +58.45%